Literature DB >> 7746283

Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions.

R Bai1, G F Taylor, J M Schmidt, M D Williams, J A Kepler, G R Pettit, E Hamel.   

Abstract

We have prepared [3H]dolastatin 10 and examined its interactions with tubulin. Binding kinetics appeared to be biphasic, with a rapid initial reaction that could not be accurately measured, followed by a slower second reaction. Bound drug was stable in centrifugal gel filtration, column gel filtration, and high performance liquid chromatography gel filtration, but the bound drug could be displaced by an active isomer of dolastatin 10. Scatchard analysis of binding data was consistent with two classes of binding sites. However, dolastatin 10 induced an aggregation reaction upon binding to tubulin, complicating analysis of the data, and incorporation of [3H]dolastatin 10 into large aggregates was readily demonstrated. The chromatographic properties of the smallest radiolabeled species that could be documented were most consistent with a complex consisting of two molecules of alpha/beta-tubulin dimer and two molecules of [3H]dolastatin 10. The coexistence of an aggregation reaction with a binding reaction at a single site probably underlies the biphasic binding kinetics and the biphasic Scatchard plot. Of peptides that strongly inhibit tubulin polymerization (dolastatin 10, dolastatin 10 isomers, segments, and analogs, dolastatin 15, and phomopsin A), only those previously shown to be strong inhibitors of vinblastine binding and nucleotide exchange also strongly inhibited [3H]dolastatin 10 binding and induced tubulin aggregation (dolastatin 10 itself, two chiral isomers of dolastatin 10, and phomopsin A). The morphology of dolastatin 10-induced aggregates was compared with that of vinblastine-induced aggregates under a variety of reaction conditions. With both drugs the aggregates had a more organized appearance when microtubule-associated proteins were included in the reaction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7746283

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

Review 1.  Antimicrotubular drugs binding to vinca domain of tubulin.

Authors:  Suvroma Gupta; Bhabatarak Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

2.  Demonstration of microtubule-like structures formed with (-)-rhazinilam from purified tubulin outside of cells and a simple tubulin-based assay for evaluation of analog activity.

Authors:  Michael C Edler; Guangli Yang; M Katherine Jung; Ruoli Bai; William G Bornmann; Ernest Hamel
Journal:  Arch Biochem Biophys       Date:  2009-06-02       Impact factor: 4.013

3.  Interactions of halichondrin B and eribulin with tubulin.

Authors:  Ruoli Bai; Tam Luong Nguyen; James C Burnett; Onur Atasoylu; Murray H G Munro; George R Pettit; Amos B Smith; Rick Gussio; Ernest Hamel
Journal:  J Chem Inf Model       Date:  2011-05-13       Impact factor: 4.956

4.  Interaction of diazonamide A with tubulin.

Authors:  Ruoli Bai; Zobeida Cruz-Monserrate; William Fenical; George R Pettit; Ernest Hamel
Journal:  Arch Biochem Biophys       Date:  2019-12-09       Impact factor: 4.013

5.  Microtubule binding and disruption and induction of premature senescence by disorazole C(1).

Authors:  Marni Brisson Tierno; Carolyn A Kitchens; Bethany Petrik; Thomas H Graham; Peter Wipf; Fengfeng L Xu; William S Saunders; Brianne S Raccor; Raghavan Balachandran; Billy W Day; Jane R Stout; Claire E Walczak; Alexander P Ducruet; Celeste E Reese; John S Lazo
Journal:  J Pharmacol Exp Ther       Date:  2008-12-09       Impact factor: 4.030

6.  (-)-Rhazinilam and the diphenylpyridazinone NSC 613241: Two compounds inducing the formation of morphologically similar tubulin spirals but binding apparently to two distinct sites on tubulin.

Authors:  Ruoli Bai; Ernest Hamel
Journal:  Arch Biochem Biophys       Date:  2016-06-13       Impact factor: 4.013

7.  HIV-1 rev depolymerizes microtubules to form stable bilayered rings.

Authors:  N R Watts; D L Sackett; R D Ward; M W Miller; P T Wingfield; S S Stahl; A C Steven
Journal:  J Cell Biol       Date:  2000-07-24       Impact factor: 10.539

8.  Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

Authors:  M Kobayashi; T Natsume; S Tamaoki; J Watanabe; H Asano; T Mikami; K Miyasaka; K Miyazaki; M Gondo; K Sakakibara; S Tsukagoshi
Journal:  Jpn J Cancer Res       Date:  1997-03

9.  Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

Authors:  T Natsume; J Watanabe; S Tamaoki; N Fujio; K Miyasaka; M Kobayashi
Journal:  Jpn J Cancer Res       Date:  2000-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.